¼¼°èÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¾÷°è ºÐ¼®(Á¦Ç° Á¾·ùº°, Åõ¿© °æ·Îº°, Áúȯ Á¾·ùº°, ¿ëµµº°, Áö¿ªº°), ¿¹Ãø(2025-2034³â)
Vaccine Adjuvants Market Size, Share, Trends, Industry Analysis Report: By Product Type, Route of Administration, Disease Type, Application, and Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1652019
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 119 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,031,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,450,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,869,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¼¼°è ¹é½Å º¸Á¶Á¦ ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 60¾ï 3,504¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¹é½Å º¸Á¶Á¦ ½ÃÀå¿¡´Â ¸é¿ª ¹ÝÀÀÀ» Çâ»ó½Ã۱â À§ÇØ ¹é½Å¿¡ ÷°¡µÇ´Â ¹°ÁúÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ º¸Á¶Á¦´Â ƯÈ÷ µµÀüÀûÀÎ Áúº´¿¡ ´ëÇÑ ¹é½ÅÀÇ È¿´ÉÀ» Çâ»ó½Ãŵ´Ï´Ù. ¹é½Å ¼ö¿ä Áõ°¡, º¸Á¶Á¦ ±â¼ú ¹ßÀü, ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº ¾ÈÀü¼º°ú È¿´ÉÀ» °³¼±ÇÑ »õ·Î¿î º¸Á¶Á¦ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÇ Áõ°¡¿Í COVID-19¸¦ ºñ·ÔÇÑ ½ÅÈï Áúº´¿¡ ´ëÇÑ ¹é½ÅÀÇ Çʿ伺ÀÌ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¹é½Å º¸Á¶Á¦ ½ÃÀåÀÇ ¼ºÀåÀº ƯÈ÷ °¨¿°¼º Áúȯ ¹× ¾Ï ¸é¿ª¿ä¹ý¿¡ ´ëÇÑ È¿°úÀûÀÎ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â Àü ¼¼°è °¨¿°º´ ¹ßº´·ü Áõ°¡, ¹é½Å È¿´É Çâ»ó¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¹é½Å °³¹ß¿¡ ´ëÇÑ Á¤ºÎ ¹× ¹Î°£ ºÎ¹®ÀÇ Áö¼ÓÀûÀÎ ÅõÀÚ¸¦ µé ¼ö ÀÖ½À´Ï´Ù. ¹é½Å º¸Á¶Á¦ ½ÃÀå °³Ã´ÀÇ ±âȸ´Â ´õ ³ªÀº ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» °¡Áø Â÷¼¼´ë º¸Á¶Á¦ °³¹ß°ú ¾Ï ¹é½ÅÀ» Æ÷ÇÔÇÑ ¸ÂÃãÇü ÀÇ·á¿¡¼­ º¸Á¶Á¦ »ç¿ëÀÇ È®´ë¿¡ ÀÖ½À´Ï´Ù. ½ÃÀå µ¿ÇâÀ¸·Î´Â ¸®Æ÷¼Ø ±â¹Ý ¹× »çÆ÷´Ñ ±â¹Ý º¸Á¶Á¦ µî º¸´Ù Áøº¸µÈ º¸Á¶Á¦ ±â¼ú·ÎÀÇ Àüȯ°ú »õ·Î¿î °Ç°­ À§Çù¿¡ ´ëÀÀÇϱâ À§ÇÑ ¹é½Å ¿¬±¸ÀÇ È®´ë°¡ ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ÀÌ ½ÃÀåÀº ±â¼ú Çõ½Å, Àü·«Àû Á¦ÈÞ, ¼¼°è ÀÇ·á ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î ²ÙÁØÈ÷ ¼ºÀåÇÒ ¼ö ÀÖ´Â ¿©°ÇÀ» °®Ãß°í ÀÖ½À´Ï´Ù.

¹é½Å º¸Á¶Á¦ ½ÃÀå : ºÐ¼® °³¿ä

Á¦Ç° À¯Çüº°·Î º¸¸é ¸í¹Ý ºÐ¾ß´Â ¹é½Å¿¡ ¿À·£ ±â°£ »ç¿ëµÇ¾î ¾ÈÀü¼ºÀÌ ÀÔÁõµÇ¾î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª º¸Á¶Á¦ ¿¡¸ÖÀüÀº °¨¿°º´ ¹× Àü¿°º´ ¹é½Å¿¡¼­ ¸é¿ª ¹ÝÀÀ °­È­¿¡ ÈûÀÔ¾î °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù.

Åõ¿© °æ·Îº°·Î´Â µ¶°¨, COVID-19 µî ´Ù¾çÇÑ °¨¿°º´ ¹é½Å¿¡ ³Î¸® »ç¿ëµÇ´Â ±ÙÀ° ³» Åõ¿© °æ·Î°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÇÇÇÏ Åõ¿©´Â ƯÈ÷ Ä¡·á¿ë ¹é½Å ¹× ¸é¿ª¿ä¹ý¿¡ Àû¿ëµÉ ¶§ °¡Àå ³ôÀº ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

Áúº´ À¯Çüº°·Î´Â ÀÎÇ÷翣ÀÚ, °£¿°, COVID-19¿Í °°Àº Áúº´¿¡ ´ëÇÑ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÌ ÁøÇàµÊ¿¡ µû¶ó °¨¿°¼º Áúȯ ºÐ¾ß°¡ ¹é½Å º¸Á¶Á¦ ½ÃÀåÀÇ ¸ÅÃâ Á¡À¯À²À» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¾Ï ºÐ¾ß´Â ¸é¿ª¿ä¹ý ¹é½Å°ú ¸ÂÃãÀÇ·áÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î °¡Àå ³ôÀº ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

º¸Á¶Á¦¸¦ ÷°¡ÇÑ ¹é½ÅÀÌ Àü ¼¼°è °øÁߺ¸°Ç Ȱµ¿¿¡¼­ ³Î¸® »ç¿ëµÊ¿¡ µû¶ó, ¿ëµµº°·Î´Â »ó¾÷¿ë ÀÀ¿ë ºÐ¾ß°¡ ¹é½Å º¸Á¶Á¦ ½ÃÀå Á¡À¯À²À» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸¿ë ºÐ¾ß´Â ¹é½Å °³¹ß ¹× ÀÓ»ó½ÃÇè, ƯÈ÷ ¾Ï ¹é½Å°ú Ä¡·á¿ë ¹é½Å¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿¡ ÈûÀÔ¾î °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â °­·ÂÇÑ ÀÇ·á ÀÎÇÁ¶ó¿Í ¹é½Å ¿¬±¸ ÅõÀÚ·Î ÀÎÇØ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ¼ö¿ä È®´ë, Àα¸ Áõ°¡, ¹é½Å äÅà Áõ°¡·Î ÀÎÇØ °¡Àå ³ôÀº ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºÐ¼® ¹æ¹ý

Á¦4Àå ¹é½Å º¸Á¶Á¦ ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå : Á¦Ç° Á¾·ùº°

Á¦6Àå ¼¼°èÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå : Åõ¿© °æ·Îº°

Á¦7Àå ¼¼°èÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå : Áúȯ Á¾·ùº°

Á¦8Àå ¼¼°èÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå : ¿ëµµº°

Á¦9Àå ¼¼°èÀÇ ¹é½Å º¸Á¶Á¦ ½ÃÀå : Áö¿ªº°

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global vaccine adjuvants market size is expected to reach USD 6,035.04 million by 2034, according to a new study by Polaris Market Research. The report "Vaccine Adjuvants Market Size, Share, Trends, Industry Analysis Report: By Product Type (Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Alum, and Others), Route of Administration, Disease Type, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The vaccine adjuvants market involves substances added to vaccines to enhance immune responses. These adjuvants improve the efficacy of vaccines, particularly for challenging diseases. Growing demand for vaccines, advancements in adjuvant technologies, and increased awareness of immunization are driving market growth. Key players focus on developing new adjuvants with improved safety and effectiveness. The market is fueled by rising vaccination programs and the need for vaccines against emerging diseases, including COVID-19.

The vaccine adjuvants market growth is driven by the increasing demand for effective vaccines, particularly for infectious diseases and cancer immunotherapy. Key drivers include the rising incidence of infectious diseases across the world, increasing need for enhanced vaccine efficacy, and continued government and private sector investments in vaccine development. Vaccine adjuvants market opportunities lie in the development of next-generation adjuvants with better safety profiles and the growing use of adjuvants in personalized medicine, including cancer vaccines. Market trends include a shift toward more advanced adjuvant technologies, such as liposome-based and saponin-based adjuvants, and the expansion of vaccine research in response to emerging health threats. Overall, the market is poised for steady growth, supported by innovation, strategic collaborations, and increasing healthcare needs worldwide.

Vaccine Adjuvants Market Report Highlights

Based on product type, the alum segment holds the largest market share due to its long-standing use in vaccines and proven safety. However, adjuvant emulsions are the fastest-growing segment, driven by their enhanced immune response in vaccines for infectious diseases and pandemics.

By route of administration, the intramuscular route segment dominates the market due to its widespread use in vaccines for various infectious diseases, such as influenza and COVID-19. The subcutaneous route is registering the highest growth, particularly in therapeutic vaccines and immunotherapy applications.

In terms of disease type, the infectious diseases segment dominates the vaccine adjuvants market revenue share, driven by ongoing vaccination programs for diseases such as influenza, hepatitis, and COVID-19. The cancer segment is experiencing the highest growth, fueled by advancements in immunotherapy vaccines and personalized medicine.

The commercial application segment, by application, leads the vaccine adjuvants market share owing to the widespread use of adjuvanted vaccines in public health initiatives globally. The research application segment is growing the fastest, supported by increased investments in vaccine development and clinical trials, especially in cancer and therapeutic vaccines.

North America holds the largest market share due to its strong healthcare infrastructure and substantial vaccine research investments. Asia Pacific is registering the highest growth, driven by expanding healthcare needs, large populations, and increasing vaccine adoption.

Polaris Market Research has segmented the vaccine adjuvants market report on the basis of product type, route of administration, disease type, application, and region:

By Product Type Outlook (Revenue - USD Million, 2020-2034)

By Route of Administration Outlook (Revenue - USD Million, 2020-2034)

By Disease Type Outlook (Revenue - USD Million, 2020-2034)

By Application Outlook (Revenue - USD Million, 2020-2034)

By Regional Outlook (Revenue - USD Million, 2020-2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Vaccine Adjuvants Market Insights

5. Global Vaccine Adjuvants Market, by Product Type

6. Global Vaccine Adjuvants Market, by Route of Administration

7. Global Vaccine Adjuvants Market, by Disease Type

8. Global Vaccine Adjuvants Market, by Application

9. Global Vaccine Adjuvants Market, by Geography

10. Competitive Landscape

11. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â